Development and Evaluation of Solid Witepsol Nanoparticles for Gene Delivery

Area of Science:

• Biotechnology
• Nanomedicine
• Drug Delivery

Background:

• Gene therapy offers novel treatment options for diseases lacking conventional therapies.
• Non-viral delivery systems, such as cationic solid lipid nanoparticles (cSLNs), are crucial for introducing large nucleic acids into target cells.
• Optimizing cSLN formulations requires careful selection and precise amounts of components for successful gene delivery.

Purpose of the Study:

• To formulate and characterize solid Witepsol nanoparticles for gene delivery applications.
• To evaluate the efficacy of these nanoparticles as a non-viral vector for nucleic acid delivery.
• To assess the potential of cSLNs in advancing gene therapy strategies.

Main Methods:

• Solid Witepsol nanoparticles were prepared using the microemulsion dilution technique with various Witepsol grades and surfactants.
• Cationic lipid (Dimethyldioctadecylammonium bromide) was incorporated to create cationic solid lipid nanoparticles (cSLNs).
• Formulations were characterized for particle size, zeta potential, DNA binding/protection, cytotoxicity, and in vitro transfection efficiency.

Main Results:

• Prepared cSLNs exhibited particle sizes ranging from 13.43±0.06 to 68.80±0.78 nm with zeta potentials exceeding +40 mV.
• Gel retardation assays confirmed the ability of cSLNs to form compact complexes with plasmid DNA (pDNA) and protect it from DNase I degradation.
• In vitro studies demonstrated effective transfection of fibroblasts by the solid Witepsol nanoparticles.

Conclusions:

• Solid Witepsol nanoparticles formulated via microemulsion dilution are effective non-viral gene delivery vectors.
• These nanoparticles show significant potential for use in gene therapy applications.
• The study highlights the promise of cSLNs as a viable alternative to viral vectors in gene delivery.